Hyderabad, April 17 -- Global pharma major Lupin Limited (Lupin) on Thursday announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA), for drug-medical device combination products at its injectable facility in Nagpur.
The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024, the Mumbai-based Pharma company said in a release.
Lupin Managing Director Nilesh Gupta, said, "We are very pleased to have received the EIR from the US FDA for drug-device combination products at our Nagpur injectable facility. We remain committed to producing complex generic and essential products that address unmet needs."
The company has 15 state...